aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Founded in 2012 and based in central Cambridge, Cambridge Nutraceuticals focuses on developing bioavailable supplements with clinically proven benefits. Initially launching with "Ateronon," a patented form of bioavailable lycopene, the company expanded its product line in December 2015 under the brand FutureYou. Their mission is to enhance health through scientifically-backed supplements, leveraging close ties with Cambridge University to ensure rigorous research and development.
Cambridge Nutraceuticals boasts a high-profile medical board that supports its scientific endeavors. Notable achievements include the successful market introduction of multiple clinically-proven supplements and significant growth since its inception. The company's impact lies in its commitment to evidence-based health solutions, contributing to the broader nutraceutical market with products that prioritize efficacy and bioavailability.
Operating Status
Active
Main Product(s)
Supplements
Technology
Biotech
Tags
Healthtech
Model Types
eCommerce, Retail
Revenue Type(s)
Transactional, Recurring
Customer Type(s)
Consumers
Geographic Exposure
Global
When was Cambridge Nutraceuticals founded?
Cambridge Nutraceuticals was founded in 2010.
When was Cambridge Nutraceuticals’s last funding round?
Cambridge Nutraceuticals’s most recent funding round was for $1.9M (USD) in January 2018.
How much has Cambridge Nutraceuticals raised to-date?
As of July 05, 2023, Cambridge Nutraceuticals has raised a total of $2.9M (USD) since Jan 1, 2018.
Add Comparison
Total Raised to Date
$2.9M
USD
Last Update Jan 1, 2018
Last Deal Details
$1.9M
USD
Jan 1, 2018
Series Unknown
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts